Loading...
•
Sep 30, 2022
Adaptive Biotechnologies Q3 2022 Earnings Report
Reported solid growth in both business areas and expressed confidence in the long-term outlook.
Key Takeaways
Adaptive Biotechnologies reported a 21% increase in revenue compared to the third quarter of the prior year. The company is focused on driving growth and innovation with a clear path to profitability.
Revenue of $47.8 million, a 21% increase from the third quarter 2021.
clonoSEQ test volume grew 52% versus the third quarter of prior year.
Signed partnership with Epic to integrate the clonoSEQ Assay into Epic’s comprehensive electronic medical record (EMR) system.
Immune Medicine business grew 18% versus the third quarter 2021, driven by drug discovery and pharma services.
Revenue by Segment
Forward Guidance
Adaptive Biotechnologies narrows full year 2022 revenue to be in the range of $185 million to $190 million compared to the previous expectation of $185 million to $195 million. We now expect full year 2022 operating expenses to be below $400 million compared to the previous expectation of between $410 million and $415 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...